Scipher Medicine
Precision Medicine · Health Care
$122Mtotal raised · 6 rounds on record
$5.8Mlatest round · Venture round · May 2024 · 2 yr ago
3backers · aMoon, Hitachi Ventures
68team · US Form 5500 (plan participants) · Dec 2024
Overview
Transforming Treatment in Immunology. Living at the crossroads of precision medicine and AI, Scipher Medicine is a precision immunology company on a mission to match each patient with their most effective therapy.
Funding and backers
Total raised
$122M
6 rounds on record
Latest round
$5.8M
Venture round · May 2024 · 2 yr ago
Team
68
US Form 5500 (plan participants) · Dec 2024
Backers
3
aMoon, Hitachi Ventures
The money's age
Long since its last round
30 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Mar 10
Partnership Scipher Medicine and Senelix Announce Strategic Collaboration to Advance SL300 Development · tennessean.com
Sep 11, 2025
Partnership Scipher Medicine and Maxymune Therapeutics Announce Strategic Collaboration to Accelerate Target Discovery in Autoimmune and Inflammatory Diseases · sciphermedicine.com
Aug 21, 2025
Launched Scipher Medicine Launches ClinicalTrialRank.com: A Breakthrough AI Platform to Predict Clinical Trial Failure and Revolutionize Drug Development Inve… · sciphermedicine.com
Jun 18, 2025
Launched Scipher Medicine Unveils New Tool to Predict Rheumatoid Arthritis Treatment Success at EULAR 2025 · sciphermedicine.com
Jun 11, 2025
Partnership Scipher Medicine Announces Collaboration with Top-Three Pharmaceutical Company to Integrate Precision Medicine into Clinical Trial Design · sciphermedicine.com
Apr 15, 2025
Partnership Scipher Medicine and Kythera Labs Partner to Unlock New Insights into Autoimmune Disease-Specific Treatment · sciphermedicine.com
Jan 13, 2025
Partnership Scipher Medicine and Roivant Partner to Bring Precision Medicine Insights to Rheumatology Drug Discovery and Development · sciphermedicine.com
Jan 9, 2025
Partnership OMNY Health and Scipher Medicine Partner to Revolutionize Autoimmune Disease Treatment with Clinico-Transcriptomics Data · sciphermedicine.com
Dec 18, 2024
Partnership Scipher Medicine and Atropos Health Partner to Accelerate Precision Medicine and Expand the Immunology Multimodal Network · sciphermedicine.com
Jul 31, 2024
Launched Scipher Medicine Launches a New Approach to Discover Treatment-Response-Predicting Biomarkers for Complex Diseases · sciphermedicine.com
May 2, 2024
Raised a round Venture round $5.8M · SEC Form D
Jan 9, 2023
Acquisition Scipher Medicine Acquires CrossBridge and its SaaS Platform to Collect and Map Patient Molecular, Outcomes and Claims Data in Real Time · businesswire.com
Mar 12, 2021
Raised a round Venture round $82M · SEC Form D
May 8, 2019
Raised a round Venture round $25M · SEC Form D
Aug 3, 2018
Raised a round Venture round $8.5M · SEC Form D
May 9, 2018
Took on debt financing $795k · SEC Form D
Oct 20, 2016
Raised a round Venture round $575k · SEC Form D
2013
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | May 2024 | $5.8M | — | SEC Form D |
| Venture round | Mar 2021 | $82M | — | SEC Form D |
| Venture round | May 2019 | $25M | — | SEC Form D |
| Venture round | Aug 2018 | $8.5M | — | SEC Form D |
| Debt Financing | May 2018 | $795k | — | SEC Form D |
| Venture round | Oct 2016 | $575k | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Scipher Medicine Corp | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Alif SalehExecutive Officer, DirectorSEC Form D
Byron KalogerouExecutive OfficerSEC Form D
Jeffrey SachsExecutive OfficerSEC Form D
Reginald SeetoExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
aMoon 
Hitachi Ventures 
Optum Ventures Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Solid IO is transforming precision oncology with organ-on-chip technology, delivering real-time, patient-specific insights to improve…
Meet Vesynta, the UK team behind DosoLogic and PMX.Community, building a model-informed precision dosing ecosystem for safer, personalised…
Genomate helps physicians find the right targeted therapy for every cancer patient based on the individual molecular profile of their…
Okomera turns tumor response into treatment decisions. Its proprietary platform acts as a decentralized lab for clinicians and biopharma…
By testing the response of a patient’s own cancer cells against many treatment options, we help physicians and patients make truly informed…
Biostate AI connects samples, data, and decisions to redefine precision health.
Visa sponsorship
2
H-1B filings in 12 months
$163k
Median offered salary
0
Open roles in United States
Who they sponsor
Data scientists
2
In the register as Scipher Medicine Corporation, Burlington, MA
Other sponsors in the same field
Belay Diagnostics 
Hope Bridge
Alert me
US Department of Labor · latest filing Jul 30, 2025 · Visa details by country
Financials
Total raised
$122.8M
Latest round
Venture - Series Unknown
Funding rounds
6
People
Alif Saleh
Executive Officer, Director
Byron Kalogerou
Executive Officer
Jeffrey Sachs
Executive Officer
Reginald Seeto
Executive Officer, Director
Miklos Kobor
Director
Albert Laszlo Barabasi
Director
Joseph Loscalzo
Director
Samir Kaul
Director
Michael Rubin
Director
Todd Sone
Director
Ingo Chakravarty
Director
Glenn Muir
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Chemomab Therapeutics And Scipher Medicine To Merge To Advance Nebokitug In AI-Powered RA Trial
Chemomab Therapeutics and Scipher Medicine announced a definitive merger agreement in a stock transaction. Upon completion, the combined company is expected to operate as Scipher Medicine Corporation and trade on Nasdaq under the ticker symbol SCIP.
Read more
Report
Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis
Combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid arthritis (RA) by leveraging Scipher's AI Network Medicine platform designed to reduce risk and significantly incre
Read more
Report
Chemomab Therapeutics and Scipher Medicine Merger Announcement Conference Call - 1769120
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder characterized by persistent synovial inflammation and erosion of bone and cartilage, leading to joint destruction and disability. Management focuses on reducing pain and limiting disa
Read more
Report
Scipher Medicine Shares Published Data Further Validating RA Patient Outcome Improvement With PrismRA Testing
FOR IMMEDIATE RELEASE Every patient deserves a treatment they know will work for them." Reg Seeto, CEO, Scipher Medicine BURLINGTON, MA, UNITED STATES /EINPresswire.com/ - Scipher Medicine, a leader in precision medicine for autoimmune diseases, today ann
Read more
Report
Scipher Medicine and Senelix Announce Strategic Collaboration to Advance SL300 Development
FOR IMMEDIATE RELEASE Scipher Medicine and Senelix Announce Strategic Collaboration to Advance SL300 Development Baltimore, MD, March 10th, 2026 - Scipher Medicine and Senelix today announced a strategic collaboration to incorporate Scipher's AI network p
Read more
Report
Scipher Medicine and Senelix Announce Strategic Collaboration to Advance SL300 Development
Read more
Report
Spectra Target Discovery Platform De-Risks Investment Decisions by Predicting Avoidable Clinical Trial Failures
Drug discovery and development remains one of the most challenging and resource-intensive processes in modern medicine. With development timelines spanning 10-15 years and costs exceeding $1-3 billion per approved drug1, the need for more efficient target
Read more
Report
Scipher Medicine and Maxymune Therapeutics Announce Strategic Collaboration to Accelerate Target Discovery in Autoimmune and Inflammatory Diseases
BURLINGTON, Mass.-(BUSINESS WIRE)-Scipher Medicine, a pioneer in network-based and AI-driven precision immunology, today announced a strategic collaboration with Maxymune Therapeutics, a biotechnology company focused on research and development of novel t
Read more
Report
Scipher Medicine Launches ClinicalTrialRank.com: A Breakthrough AI Platform to Predict Clinical Trial Failure and Revolutionize Drug Development Investment Strategy
WALTHAM, Mass.-(BUSINESS WIRE)-Scipher Medicine, a leader in precision immunology, today announced the public launch of ClinicalTrialRank.com, an innovative artificial intelligence (AI) platform engineered to predict clinical trial failure with unpreceden
Read more
Report
Scipher and Savant Bio Partner to Build the Most Comprehensive Clinico-Genomic Dataset in Rheumatoid Arthritis
NEW YORK & WALTHAM, Mass.-(BUSINESS WIRE)-Scipher Medicine, a leader in precision immunology, and Savant Bio, a Roivant-backed health data infrastructure company, today announced an expanded strategic partnership to build the world's most advanced clinico
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Boston
United States
HQ
200-500 est. staff